New weekly injection shows promise for boosting growth in kids with dwarfism
NCT ID NCT05598320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could receive the drug in an open-label extension.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Saint Paul, Minnesota, 55102, United States
-
Ascendis Pharma Investigational Site
Columbia, Missouri, 65212, United States
-
Ascendis Pharma Investigational Site
Houston, Texas, 77030, United States
-
Ascendis Pharma Investigational Site
Madison, Wisconsin, 53705, United States
-
Ascendis Pharma Investigational Site
Parkville, 3052, Australia
-
Ascendis Pharma Investigational Site
Montreal, H3T 1CS, Canada
-
Ascendis Pharma Investigational Site
Copenhagen, 2100, Denmark
-
Ascendis Pharma Investigational Site
Dublin, D01 YC76, Ireland
-
Ascendis Pharma Investigational Site
Auckland, 1023, New Zealand
-
Ascendis Pharma Investigational Site
Vitoria-Gasteiz, 1008, Spain